Sleven, the reason for the BRAVE study is related to the next sentence - which you left out of your quote:
"However, it is not clear whether EPA beneficially affects these processes or cognitive performance in cognitively-healthy adults at increased risk for AD"
Of this study will give researchers the idea or green light on whether to go on and study EPA with a larger and/or sicker group. The Biogen study talked about today was quite different in that the patients in the study already had AD. Much easier to sell a drug to patients that have a condition than to promote something that might reduce the chance they get a condition (prevention) as we all know.
News 
Market Data 
Discover 
